Author ORCID Identifier

https://orcid.org/0000-0001-5876-8256

Date Available

5-15-2026

Year of Publication

2025

Document Type

Doctoral Dissertation

Degree Name

Doctor of Philosophy (PhD)

College

Medicine

Department/School/Program

Toxicology and Cancer Biology

Faculty

David Orren, advisor

Faculty

Isabel Mellon, DGS

Abstract

Cigarette smoke contains over 7,000 chemicals, many being carcinogens and proinflammatory agents contributing to chronic respiratory diseases like COPD and lung cancer. This study investigated responses of human bronchial epithelial cells (HBECs) to cigarette smoke condensate (CSC), focusing on oxidative stress and NF-κB signaling. Three HBEC lines were exposed to non-cytotoxic CSC doses for 48 hours, inducing morphological changes consistent with epithelial-to-mesenchymal transition (EMT). RNA sequencing revealed transcriptomic shifts in all cell lines, particularly affecting genes related to oxidative stress, inflammation, hypoxia, and metabolism. Enrichment analyses confirmed activation of NRF2 antioxidant, NF-κB and IL-17 inflammatory, and hypoxiainducible factor pathways, indicating a coordinated stress response. Protein analyses confirmed increased phosphorylated NF-κB p65 expression in CSCtreated HBEC3KT cells. Scratch wound assays demonstrated enhanced migratory ability following CSC exposure, while decreases in E-cadherin and increases in vimentin supported partial EMT induction. Cell viability assays showed moderate cytotoxicity after 48-hour CSC treatment, with HBEC2 being most sensitive. Results suggest a state of chronic cellular stress, inflammation, and hypoxia with impaired epithelial restitution—hallmarks of early airway remodeling in smoke-related lung pathologies. This integrated analysis provides mechanistic insights into early events driving airway injury in smokers and may inform therapeutic strategies targeting epithelial resilience.

Digital Object Identifier (DOI)

https://doi.org/10.13023/etd.2025.215

Funding Information

Food and Drug Administration (FDA), grants UC2FD005049 and UC2FD005671

Available for download on Friday, May 15, 2026

Share

COinS